HPP737 Substance Balance Study in Human

StatusUnknown
PhaseNot applicable
Started

Record status This record was last updated September 4, 2024 (before its estimated July 30, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Main research purpose 1. Quantitative analysis of the total amount of radioactivity in excreta (urine and feces) of male healthy subjects after oral administration of \[14C\]HPP737, to obtain the cumulative excretion rate and main excretion routes of human radioactivity; 2. To identify the main metabolites in the offspring of \[14C\]HPP737 in healthy male subjects, and to determine the main biotransformation pathway and main metabolite structure; 3. To investigate the distribution of total radioactivity in whole blood and plasma and the pharmacokinetics of total plasma radioactivity in healthy male subjects after a single oral administration of \[14C\]HPP737. Participants will: 1. Take Investigational product once 2. Stay in the clinic about 7 days for checkups and tests 3. Report their symptoms
Trial Details
NCT Number NCT06584058
Lead Sponsor Newsoara Biopharma Co., Ltd.
Conditions
(from sponsor)		 Psoriasis
Related terms Psoriasis
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov